On March 6, 2026, Health Minister Kenichiro Ueno announced at a post-cabinet press conference that Japan had granted conditional, time-limited manufacturing and marketing approval to two regenerative medicine products made from iPS cells.

The two are ReHeart, a cardiac muscle sheet for severe heart failure developed by Cuorips, and Amshepri, dopaminergic neural progenitor cells for Parkinson's disease developed by Sumitomo Pharma and RACTHERA. No iPS cell-derived regenerative medicine product had ever been approved anywhere before.

Ueno told reporters he was delighted that a treatment born in Japan from Professor Yamanaka's iPS cells had become the world's first of its kind to reach practical use, and said he hoped it would help patients not only in Japan but around the world.

The approval followed the February 19 sign-off by the Committee on Regenerative Medicine Products and Biotechnology under the health ministry's Pharmaceutical Affairs Council. If the committee's endorsement was a letter of recommendation, the minister's approval is the acceptance letter.

The Two Products at a Glance

ReHeart: A "Repair Patch" for the Heart

ReHeart comes from Cuorips, a Tokyo-based startup spun out of Osaka University.

Cardiac muscle cells are cultured from a healthy donor's iPS cells and processed into a sheet 4 to 5 centimeters across and about 0.1 millimeters thick. Surgeons open the left chest and apply it directly to the surface of the heart. Cytokines secreted by the sheet promote the formation of new blood vessels, restoring pumping function in a weakened heart.

It targets severe heart failure from ischemic cardiomyopathy that has not responded adequately to standard care, including drugs and invasive procedures. Blocked vessels starve the heart of blood and the muscle deteriorates. Until now, such patients were left with a transplant or a ventricular assist device: transplants face donor shortages and age limits, and assist devices carry risks of infection and neurological damage.

Between 2020 and 2023, eight patients were treated in a trial across four sites led by Osaka University Hospital. All showed improvement, with no evidence of tumor formation.

Amshepri: Planting Neural "Seeds" in the Brain

Amshepri, generic name rageneprocel, was developed by Sumitomo Pharma of Osaka and RACTHERA of Tokyo, building on research by Professor Jun Takahashi and colleagues at Kyoto University's Center for iPS Cell Research and Application (CiRA). It is manufactured from iPS cell stock supplied by the Kyoto University iPS Cell Research Foundation.

Dopaminergic neural progenitor cells are derived from iPS cells, and 5 to 10 million of them are implanted through small holes in the skull into the putamen on both sides of the brain via stereotactic surgery. Once there, the cells mature into neurons that secrete dopamine, easing the motor symptoms of Parkinson's.

It targets improvement of off-period motor symptoms in advanced Parkinson's patients for whom existing drug therapy, including levodopa preparations, is insufficient.

Seven patients were treated at Kyoto University Hospital between 2018 and 2023. Among the six evaluated for efficacy, four showed improved motor function, and PET scans confirmed dopamine production by the transplanted cells. No tumors formed. The results appeared in Nature in April 2025. Documents submitted to Japan's Central Social Insurance Medical Council frame it slightly differently: three of the six exceeded the placebo effect reported in earlier literature at the two-year mark.

The name Amshepri combines "ameliorate" with Khepri, the ancient Egyptian sun god symbolizing creation and rebirth.

55.3 Million Yen: The World's First Reimbursed iPS Product

About two months after approval, on May 13, 2026, the Central Social Insurance Medical Council approved reimbursement pricing for Amshepri: 55,306,737 yen for a set of 18 vials. Being the world's first iPS-derived regenerative medicine product earned it a 10 percent pioneer premium and a 10 percent marketability premium. Listing took effect May 20, making it the first iPS cell-derived product covered by public insurance anywhere. Peak usage is projected at 133 patients and 7.4 billion yen in sales.

That 55.3 million yen covers the product alone. Hospitalization, the stereotactic surgery, and pre- and post-operative testing are billed separately. Japan's high-cost medical expense benefit caps what patients actually pay, bringing out-of-pocket costs down to somewhere between tens of thousands and a few hundred thousand yen a month depending on income.

ReHeart is being processed as a medical device rather than a drug. Cuorips expects its price to be set around summer 2026 and plans to begin domestic sales in the autumn. It has completed preliminary consultations with the US Food and Drug Administration and is looking abroad.

For now, few facilities and physicians can deliver either treatment. Amshepri falls under optimal-use promotion guidelines and can only be administered at sites with dedicated infrastructure, so not everyone who wants it will get it soon.

Conditional Approval, and the Objections It Drew

Both products went through Japan's conditional and time-limited approval scheme, which grants provisional approval once safety is confirmed and efficacy can be "presumed" from small trials.

Within seven years, by March 5, 2033, ReHeart must complete post-marketing surveillance on roughly 75 cases and Amshepri on 35, re-establishing efficacy and safety. Fall short and full approval never comes; approval can be withdrawn. Every case must be tracked, and treating institutions and physicians must meet structural requirements. ReHeart carries additional obligations around mechanism-of-action data and manufacturing quality.

Criticism of the scheme runs deep. Of the six regenerative medicine products previously approved this way, two were withdrawn after failing to demonstrate efficacy, and the remaining four are still under surveillance. None has yet converted to full approval.

This round drew objections too. On April 6, 2026, the citizens' group Medwatcher Japan submitted a written opinion to the health minister and the council chair demanding that both approvals be revoked and reimbursement denied. On Amshepri, it argued that the trial was a single-arm, open-label, two-year study with no control group, that safety was the primary endpoint while efficacy was only secondary, and that with just six patients in the efficacy analysis there is no way to separate a real treatment effect from chance. Nature's news section and Hiroshi Kawaguchi, writing in Medical Tribune, raised similar doubts. Whether efficacy can honestly be "presumed" remains an open question.

20 Years in the Making

Shinya Yamanaka, the Kyoto University professor emeritus who created iPS cells and formerly directed CiRA, said after the February 19 committee decision that he was delighted, twenty years on from the announcement, to witness a major step toward putting the technology into society.

Two decades have passed since he generated iPS cells from mouse cells in 2006. The Japanese government has invested more than 110 billion yen (about $710 million) in iPS research, pairing legal groundwork with research funding.

Sumitomo Pharma is also running an Amshepri trial at the University of California, San Diego, and projects sales above 100 billion yen (about $650 million) from that product alone in the 2030s. Across its whole iPS portfolio, it targets up to 350 billion yen (about $2.3 billion) by 2040.

Patients with severe heart failure who could only wait for a transplant, and Parkinson's patients watching their medication lose its grip, now have another option. Whether it is a real one will be decided by the data that accumulates over the next seven years.

Japan has taken a historic step in iPS-based regenerative medicine. What is the debate around regenerative medicine and stem cell therapy in your country? We'd love to hear your thoughts on access to advanced treatments and who should bear the cost.

References